Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 14051-14057
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.14051
Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis
Xing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai
Xing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai, Clinical Liver Center, 180th Hospital of People’s Liberation Army, Quanzhou 362000, Fujian Province, China
Author contributions: Pan XN designed research; Zheng LQ performed research; ZhengLQ and Lai XH contributed analytic tools; Zheng LQ analyzed data and wrote the paper.
Correspondence to: Xin-Nan Pan, Professor, Clinical Liver Center, 180th Hospital of People’s Liberation Army, FengZe Zone Huayuan Rd No. 180, Quanzhou 362000, Fujian Province, China. xnpancn@163.com
Telephone: +86-21-28919421 Fax: +86-21-28919421
Received: April 27, 2014
Revised: June 20, 2014
Accepted: July 16, 2014
Published online: October 14, 2014
Core Tip

Core tip: Out of 78 studies identified, five studies were included in the final analysis, which showed that the mean decline in scores for the model for end-stage liver disease was -1.23 [95%CI: -2.45-(-0.01)], -1.87 [95%CI: -3.16-(-0.58)], -2.01 [95%CI: -3.35-(-0.68)] at 2, 4 and 24 wk, respectively. The mean improvement in albumin levels was -0.28, 2.60, 5.28, 4.39 g/L at the end of 8, 16, 24, and 48 wk, respectively. Alanine aminotransferase, total bilirubin levels and prothrombin times improved to some extent. Bone marrow-derived mesenchymal stem cell injections resulted in no serious adverse events or complications.